Welcome to our dedicated page for Sientra news (Ticker: SIEN), a resource for investors and traders seeking the latest updates and insights on Sientra stock.
Sientra, Inc. (NASDAQ: SIEN) is a surgical aesthetics company headquartered in Irvine, California. The company is dedicated to developing innovative and safe solutions aimed at achieving the best aesthetic outcomes. Sientra's diverse product portfolio includes round and shaped breast implants, the first fifth-generation breast implants approved by the FDA for sale in the United States, and the groundbreaking AlloX2® breast tissue expander with patented dual-port and integral drain technology. The company also offers the next-generation AlloX2Pro™, the first and only FDA-cleared MRI-compatible tissue expander, the Viality™ with AuraClens™ enhanced viability fat transfer system, and the SimpliDerm® Human Acellular Dermal Matrix. One of the flagship products in its lineup is BIOCORNEUM, the top-performing and most recommended scar gel by plastic surgeons.
In recent developments, Sientra has reported substantial progress toward sustainable and profitable growth. The second quarter of 2023 marked the twelfth consecutive quarter of year-over-year revenue growth, largely driven by strong performance in reconstruction and despite a decline in elective cash pay aesthetics procedures. New products like Viality™ and SimpliDerm® have received positive feedback and are expected to boost the company's long-term growth and solidify its leading position in the reconstruction market.
The company's financial condition has shown improvement, with effective measures in place to reduce operating expenses. Total net sales for the full year 2023 are expected to be between $98 million to $102 million, reflecting an annual growth rate of 8% to 13%. Sientra's operating spend is forecasted to be significantly lower, demonstrating the firm's commitment to long-term profitability. Despite some market softness in the augmentation segment, Sientra remains focused on enhancing its financial footing and strategic partnerships.
One of the significant steps taken by Sientra to ensure operational continuity during its Chapter 11 proceedings is securing $22.5 million in debtor-in-possession financing from existing lenders. This fund will support ongoing operations during the sale process, aiming for increased financial stability and long-term success under new ownership. The company has also announced a definitive agreement with Tiger Aesthetics Medical, LLC and Nuance Intermediary, LLC for the sale of its breast reconstruction and BIOCORNEUM businesses, respectively.
Sientra continues to use its investor relations website as a primary source for disseminating important information, ensuring transparency and accessibility for investors. To learn more about Sientra, visit their website and follow them on LinkedIn, Instagram, and Facebook.
Sientra, a surgical aesthetics company, announced FDA approval for its Low Plus Profile Projection Breast Implant, aimed at breast augmentation and reconstruction. Set to launch in late July 2022, this implant addresses a gap between low and moderate profile options, allowing for greater customization. Sientra will be the first U.S. company to offer 80cc and 110cc gel implants, further enhancing its product portfolio. This move is expected to boost Sientra's market share as breast augmentation procedures surged by 41% from 2020 to 2021, solidifying its growth in the competitive plastic surgery market.
Sientra, Inc. (NASDAQ: SIEN) will participate in the William Blair 42nd Annual Growth Stock Conference from June 6-9, 2022. The company's management will deliver a live presentation on June 7, 2022, at 4:00 PM CDT / 2:00 PM PDT. An on-demand webcast of the presentation will be available on Sientra's website for 90 days afterward. Sientra specializes in medical aesthetics, offering a diverse range of products, including advanced breast implants and innovative fat grafting systems. For more details, visit www.sientra.com.
Sientra, Inc. (NASDAQ: SIEN) will participate in the 19th Annual Craig-Hallum Institutional Investor Conference on June 1, 2022. This virtual event is for prospective and existing Craig-Hallum clients. Interested parties can contact their representatives for one-on-one meetings with Sientra management.
Based in Santa Barbara, Sientra is a leader in medical aesthetics, focusing on innovative products for plastic surgery. Their offerings include FDA-approved breast implants and advanced surgical technologies, supported by strong clinical results.
Sientra, a medical aesthetics company, reported first-quarter 2022 net sales of $21.4 million, up 17% year-over-year, driven by 50% growth in reconstruction. Gross margins improved to 60% due to better operational efficiencies. The company expanded its market share in both augmentation and reconstruction, adding over 200 new accounts. Sientra aims for 2022 net sales of $93-$97 million, reflecting 15%-20% growth from 2021. However, operating expenses rose to $28.9 million, up from $21.9 million.
Sientra, Inc. (NASDAQ: SIEN) has announced its financial results for Q1 2022 will be released on May 12, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Investors can access the call by dialing +1 (877) 270-2148 for domestic calls or +1 (412) 902-6510 for international calls, using conference ID 10166923. A live webcast will be available on their Investor Relations website and will be archived afterward.
Sientra (NASDAQ: SIEN) announced that CEO Ron Menezes will present at the 2022 Virtual Growth Conference hosted by Maxim Group LLC from March 28-30, 2022. The presentation will occur during the "Aesthetics Device Industry Panel" on March 28 at 1:00 PM EDT. Interested attendees can register and view the panel on Maxim's M-Vest platform. Sientra is focused on advancing plastic surgery through innovative products, including FDA-approved breast implants and the Allox2® breast tissue expander.
Sientra, Inc. (NASDAQ: SIEN) has received approval from Health Canada to market its High-Strength Cohesive (HSC and HSC+) silicone gel breast implants in Canada, marking a significant milestone in the company’s international expansion efforts. Sientra becomes the third manufacturer in Canada, introducing advanced technologies and a strong ten-year safety data backing. The implants will be marketed in partnership with Kai Aesthetic, ensuring high safety and product standards. The approval is expected to benefit Canadian plastic surgeons and their patients.
Sientra, Inc. (NASDAQ: SIEN) reported its Q4 and full-year 2021 financial results, showcasing a 26.6% increase in Q4 net sales to $22.6 million and a 47% growth for the year to $80.7 million. The company expanded its market share in Augmentation and Reconstruction to approximately 11% and 14% respectively. Despite a loss from continuing operations of $62.5 million for the year, the cash position remains strong at $51.8 million. For 2022, Sientra anticipates net sales of $93 million to $97 million, a projected growth of 15% to 20%.
Sientra, Inc. (NASDAQ: SIEN), a medical aesthetics company, will release its financial results for Q4 and the full year of 2021 on March 23, 2022, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where they will discuss the results. Investors can access the call via dial-in numbers or a live webcast on the investor relations section of their website. Sientra focuses on providing innovative products for plastic surgery, including FDA-approved breast implants and advanced surgical tools.
Sientra, Inc. (NASDAQ: SIEN) announced preliminary financial results for Q4 and the full year 2021, projecting annual revenue of $80-$81 million, marking a significant 46%-47% growth year-over-year. The fourth-quarter revenue is anticipated to be between $22-$23 million, representing a 23%-29% increase from the same quarter in 2020. This performance is attributed to strong market demand for Sientra's Breast Products and effective commercial strategies. The company also highlighted the benefits of acquiring Auragen Aesthetics' fat grafting technology, enhancing its position in the plastic surgery market.
FAQ
What is the market cap of Sientra (SIEN)?
What does Sientra, Inc. specialize in?
Where is Sientra headquartered?
What are some of Sientra's key products?
How did Sientra perform financially in the second quarter of 2023?
What recent product launches has Sientra introduced?
How is Sientra addressing its financial challenges?
What strategic sales has Sientra recently announced?
What is Sientra’s outlook for the full year 2023?
How does Sientra ensure product safety and efficacy?
How can investors stay updated on Sientra’s latest developments?
